Please cite this article as: Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O, for the SAKK, A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PDAbstract Background: Nivolumab (NIV) was recently approved in several countries for patients with pre-